NovaBridge Biosciences · NASDAQ:NBP
NovaBridge Biosciences — Investor Presentation (February 2026)
45 slides from NovaBridge Biosciences's investor presentation, Feb 6, 2026
Slide 1: Company Presentation February 2026
Company Presentation February 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by NovaBridge Biosciences (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewin
Slide 3: Company Overview & Highlights
Company Overview & Highlights
Slide 4: Our Evolution to Pioneer the Next Frontier in Global Innovation
Notes: mAb = monoclonal antibody; bsAb = bispecific antibody; PoC = Proof of Concept; PD-L1 = programmed death-ligand 1; CLDN18.2 = Claudin18.2 Our Evolution to Pioneer the Next Frontier in Global Innovation Pivot & Focus Asset-based Model Clinical-stage China Biotech 1.0 Clinical-stage US Biotech 2
Slide 5: We Are a Hub-and-Spoke Gateway Connecting Global Markets
We Are a Hub-and-Spoke Gateway Connecting Global Markets We are the FIRST and ONLY listed hub-and-spoke platform specializing in bridging Asian innovation to the global markets Existing Partners Co-Co collaboration Acquisitions NewCo Licensing in/out … Business Development Capability (BD-in and BD-o
Slide 6: Our Platform-based Business Model
Notes: mAb = monoclonal antibody; bsAb = bispecific antibody; PD-L1 = programmed death-ligand 1; CLDN18.2 = Claudin 18.2 Driving Accelerated Development and Value Creation of Innovations in a Quality-oriented and Cross-therapeutic Approach Our Platform-based Business Model Accelerate innovative asse
Slide 7: Focusing on the Most Significant Value Creation Step
Focusing on the Most Significant Value Creation Step along the Biopharma Innovation Value Chain Our Platform-based Business Model (Cont’d) Discovery Pre-clinical development Clinical PoC Late phase development Registration Commerciali- zation Not our focus: Increasingly commoditized activities withi
Slide 8: Pipeline of Oncology and Ophthalmology Programs
Co-developed with ABL Bio (givastomig also known as ABL111, ragistomig also known as ABL503) BMS agreed to grant us the license to use, and manufacture and supply for use of nivolumab (OPDIVO®) in our Phase 1 trial to evaluate givastomig’s combination with nivolumab and mFOLFOX6 Submitted the protoc
Slide 9: Visionary and Seasoned Management Team
Visionary and Seasoned Management Team We assembled a seasoned management team composed of industry veterans with extensive regional and functional expertise Years of Industry Experience # 12 Wei Fu Director and Executive Chairman of our Board 25 Sean Fu PhD, MBA Chief Executive Officer Phillip Denn
Slide 10: Oncology Program Givastomig
Oncology Program Givastomig Claudin 18.2 X 4-1BB bsAb with Best-in-Class Potential
Slide 11: Gastric Cancer Market Opportunity
5th most common cancer with ~250k patients globally and 4th leading cause of cancer mortality worldwide1 Over 60% of patients are diagnosed at an advanced or metastatic stage2, where prognosis is poor Despite approved therapies, 5-year survival rates are only ~7%2 Growing market with $12Bn in sales
Slide 12: Zolbetuximab: First Approved CLDN18.2 mAb for Gastric Cancer
Zolbetuximab: First Approved CLDN18.2 mAb for Gastric Cancer Cut-Off of ≥1% CLDN18.2 Expression Doubles Number of Patients Eligible for Approved CLDN18.2-based Therapy Distribution of Claudin 18.2 Expression in Over 4,000 Gastric Cancer Patients Opportunity to expand and outperform other CLDN18.2 di
Slide 13: Givastomig: Broad Potential to Improve Standard-of-Care
Revised from Nat Rev Clin Oncol. 2024 May;21(5):354-369 Notes: scFv = single chain Fragment-variable region; IgG1 = Immunoglobin G1; ADCC = antibody-dependent cell-mediated cytotoxicity; CDC = complement-dependent cytotoxicity; TME = tumor microenvironment; PFS = progression free survival; CLDN18.2
Slide 14: Givastomig Phase 1b Study Design with Nivolumab + Chemotherapy
Notes: GEC = gastroesophageal cancer; GEJ = gastroesophageal junction; EAC = esophageal adenocarcinoma; mFOLFOX6 = standard of care chemotherapy regimen; nivo = nivolumab; Q2W = every two weeks; Giva = givastomig; ORR = objective response rate; PK = pharmacokinetic; PD = pharmacodynamic; BoR = best
Slide 15: First Evidence of Efficacy in Dose Escalation Cohorts
Phase 1b dose escalation data release: ESMO GI 2025, oral session First Evidence of Efficacy in Dose Escalation Cohorts ORR: % (n) Biomarker All Escalation (n=17) Cohorts Selected for Expansion (8 & 12 mg/kg, n=12) Total 71 (12/17) 83 (10/12) PD-L1 ≥5 82 (9/11) 89 (8/9) <5 50 (3/6) 67 (2/3) ≥1 73 (1
Slide 16: Combination Dose Escalation and Expansion Baseline Patient Characteristics
Feature(s) 8 mg/kg (n=27) Giva combo 12mg/kg (n=27) 12 mg/kg (n=27) 8 mg/kg or 12 mg/kg (n=54) Age Median (y) 64 58 61 Gender Male 63% 41% 52% Female 37% 59% 48% Race Asian 15% 11% 13% White 59% 63% 61% Black 7% 11% 9% NR 19% 15% 17% ECOG PS 0 52% 48% 50% 1 48% 52% 50% 2 0% 0% 0% NR 0% 0% 0% CLDN18.
Slide 17: Phase 1b Combination Efficacy Results
Cohort / Study: Givastomig Phase 1b Combination CHECKMATE-6493 SPOTLIGHT4 ILUSTRO6 8 mg/kg esc + exp (n=27) 12 mg/kg esc + exp (n=27) 8 & 12 mg/kg esc + exp (n=53) mFOLFOX6 / CapeOX + Nivo (n=789) mFOLFOX6 + Zolbe (n=283) Zolbe+Nivo+ Chemo (n=77) Efficacy-evaluable (n)1 26 26 52 71 ORR % (n) 77 (20/
Slide 18: Tumor Shrinkage in 51/52 Subjects
Biomarker Key: PD-L1 CPS < 5 or CLDN18.2 < 75 51/52 Subjects Experienced Tumor Shrinkage Notes: Data cutoff as of December 2, 2025. PD-L1 = programmed death-ligand 1; CPS = combined positive score; CLDN = Claudin 18.2;; CLDN18.2 = Claudin 18.2; SD = stable disease; uPR = unconfirmed partial response
Slide 19: Rapid Responses That Deepen Over Time
Rapid Responses That Deepen Over Time Dose level 8 mg/kg (n=26)1 12 mg/kg (n=26)2 Median time to response (mo., Min, Max) 1.8 (1.3, 7.5) 2.5 (1.5, 5.4) PD-L1 CPS ≥ 1 1.8 (1.3, 7.5) 1.8 (1.5, 3.9) PD-L1 CPS < 1 5.7 (1.7, 5.7) 3.6 (1.9, 5.4) CLDN18.2 ≥ 75 1.9 (1.5, 5.7) 1.8 (1.7, 3.9) CLDN18.2 < 75 1.
Slide 20: Promising Progression Free Survival Data Observed
Phase 1b PFS in efficacy evaluable patients Based on patients in the dose escalation and dose expansion cohorts Cohort / Study: Givastomig Phase 1b Combination Study CHECKMATE-6492 SPOTLIGHT3 ILUSTRO4 8 mg/kg esc + exp (n=27) 12 mg/kg esc + exp (n=27) 8 & 12 mg/kg esc + exp (n=53) mFOLFOX6 / CapeOX
Slide 21: Duration of Study Treatment
11 patients remain on treatment at 8 mg/kg 18 patients remain on treatment at 12 mg/kg1 Duration of Study Treatment – 29 Patients Remain on Treatment (n=53) The 12 mg/kg cohort includes one additional patient for survival analysis who was ineligible for response analysis Notes: Data cutoff as of Dec
Slide 22: Efficacy Breakdown of Givastomig vs. Zolbetuximab in 1L GEC
Efficacy Breakdown of Givastomig vs. Zolbetuximab in 1L GEC (ILUSTRO) Givastomig Efficacy Comparisons in Combination with nivolumab + FOLFOX Inclusion of CLDN high patients (≥75%) Inclusion of CLDN intermediate patients (≥ 50% - 74%) Inclusion of CLDN low patients (1% - 49%) ORR > 70% in all patient
Slide 23: Givastomig Safety: Comparable to Other 1L Combinations in GEC
Cohort/Study Givastomig Phase 1b Combination Study CHECKMATE-6491 SPOTLIGHT2 ILUSTRO3 8 mg/kg (n=27) 12 mg/kg (n=27) mFOLFOX6 / CapeOX + Nivo (n=782) mFOLFOX6 + Zolbe (n=279) Zolbe+Nivo+ Chemo (n=77) TEAE All Grades 100% 100% NA >99% 98.7% ≥ Grade 3 70% 70% NA 87% 66.2% TRAE any drug All Grades 100%
Slide 24: Givastomig Safety Profile Suitable for Combination in 1L Gastric Cancer
Givastomig Safety Profile Suitable for Combination in 1L Gastric Cancer Most common givastomig-related TRAEs were nausea, vomiting, and fatigue, with Grade 3 incidence of these AEs ≤11% Most common any drug-related TRAEs were fatigue, nausea, neutropenia Grade 3 incidence was low in each cohort (8 m
Slide 25: Givastomig Demonstrated BIC Potential in 1L GEC
Givastomig Demonstrated BIC Potential in 1L GEC Comparison of Giva + immunochemotherapy vs. Zolbe + immunochemotherapy (ILUSTRO study) Coverage: Givastomig Provides the Broadest Coverage in CLDN18.2 asset class Givastomig combinations most inclusive CLDN18.2 ≥1% at ≥1+ intensity Efficacy observed ac
Slide 26: Overall Clinical Development Plan
Overall Clinical Development Plan Program Phase 1 Phase 2 Phase 3 Anticipated Milestones Gastric Cancer CLDN18.2+ Topline Data Jan-2026 FPI Q1 2026 FPI Q4 2025 FPI 2H 2026 Other GI Malignancies CLDN18.2+ FPI 1H 2026 FPI 1H 2026 1L Dose Expansion (Giva + Nivo + Chemo) 1L Randomized Phase 2 (Giva + Ni
Slide 27: Expansion Data Reinforces Givastomig's Best-in-Class Potential
Expansion Data Reinforces Givastomig's Best-in-Class Potential Robust efficacy, with 77% ORR observed at 8 mg/kg and 73% ORR observed at 12 mg/kg Responses observed across a wide range of PD-L1 and CLDN18.2 expression levels Durable responses with 16.9-month mPFS observed at 8 mg/kg Well tolerated i
Slide 28: Givastomig Market Opportunity Notes
Markets include U.S., five E.U. countries, and Japan in 2025 based on Data Monitor Biomed Tracker, based on 1L treatment HER2-negative status of 78%. Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER-2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cance
Slide 29: Ophthalmology Program VIS-101
Ophthalmology Program VIS-101
Slide 30: Transaction Structure Visara, Inc.
Transaction Structure Visara, Inc. NovaBridge AffaMed ESOP 65% 30% 5% NovaBridge contributed cash in exchange for 65% of the equity interest in Visara AffaMed contributed its rights and interests in VIS-101 to Visara in exchange for 30% of the equity interest in Visara The remaining 5% equity intere
Slide 31: VIS-101: Best-in-Class VEGF × Ang-2 Bispecific
A novel VEGF × Ang-2 bsAb with the potential to emerge as a leading therapeutic option for multiple retinal indications that could lead to vision loss, including wet AMD, DME, and retinal vein occlusion VIS-101: Best-in-Class VEGF × Ang-2 Bispecific for Significant Ophthalmology Diseases with High U
Slide 32: China Randomized Phase Interim Analysis Shows Best-in-Class Potential
China Randomized Phase 2 Interim Analysis Shows Best-in-Class Potential BCVA (ETDRS Letters) 3 Intravitreal injections Follow-up ongoing up to 28 weeks post last injection Effective on pre-treated patients Less priming dose Longer durability Clinical Plan of VIS-101 Q1 2026: Phase 2 topline data By
Slide 33: Other Oncology Programs Ragistomig Uliledlimab
Other Oncology Programs Ragistomig Uliledlimab
Slide 34: Ragistomig: A Potential Next-Generation Immuno-oncology Backbone
ASCO 2024 poster Cancer Discovery 2022 Notes: The comparisons in the table above are not based on data from head-to-head trials and are not direct comparisons. Differences in trial designs, patient groups, trial endpoints, study sizes, and other factors may impact the comparisons. bsAb = bispecific
Slide 35: Uliledlimab: A Potential Best-in-Class CD73 Therapeutic
Patient disposition based on ASCO 2023 Poster from a cohort of 70 enrolled patients with unresectable/metastatic disease, including 67 efficacy evaluable and 64 patients who received at least one post baseline tumor assessment per iRECIST. Overall study (up to n=190) enrolled 5 cohorts (3 NSCLC sub-
Slide 36: Financial Overview and Upcoming Catalysts
Financial Overview and Upcoming Catalysts
Slide 37: Financial Overview
Financial Overview No outstanding debt Cash, cash equivalents & short-term investments To support planned operations $228.3 million1 Runway to Q4 2028 Unlevered balance sheet Represents consolidated cash balances of NovaBridge and Visara subsidiaries as of September 30, 2025
Slide 38: Near-term Catalysts
Notes: 1L = first line; GEA = Gastroesophageal adenocarcinoma, including gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma; BTC = biliary tract cancer; PDAC = pancreatic ductal adenocarcinoma; NSCLC = non-small cell lung cancer; Wet AMD = wet age-related macular degener
Slide 39: Research and Development
Ys ovabridge Research and Development
Slide 40: Our Research and Development Capabilities
Elizabeth Lindner Executive Director, Clinical Operations 10+ Xuejun Liu Executive Director, Translational Medicine 10+ Peter Sabbatini Senior Director, Clinical Biomarkers 10+ Our Research and Development Capabilities Years of Industry Experience # Claire Xu MD, PhD Senior Vice President, Clinical
Slide 41: Strategic Advantages
A ovaridge Strategic Advantages
Slide 42: Asia's largest healthcare-dedicated asset manager (CBC)
Asia’s largest and most impactful healthcare-dedicated asset manager Investor-Operator approach Build deep expertise in value-creation levers and hands-on portfolio management, securing significantly greater exposures to top-tier assets compared with peers CBC is well positioned with global resource
Slide 43: Regional Coverage Leads and Global Investment Team
Regional Coverage Leads Sean LU Senior Managing Director Greater China Billy CHO Senior Managing Director Korea Vijay KARWAL Managing Director SEA Global Investment Team Managing Directors Directors / Vice Presidents Neo ZHANG Managing Director Hao YIN Managing Director Ray JIN Managing Director Qiu
Slide 44: CBC's Leading Healthcare Ecosystem
Ophthalmology Assets Small Molecule Oncology Assets Protein Conjugates & Novel ADCs Small Molecule Oncology Assets Transformative Drugs & Vaccines Neurology & Allergy Assets NeuroGen Pharma And more … Gastrointestinal Therapeutics Specialty & Respiratory Drugs Chronic & Critical-Care Medications Cel
Slide 45: Thank you
Thank you www.novabridge.com [email protected]
NovaBridge Biosciences — Investor Presentation (February 2026) on 6ix